

---

# Familial Risk for Common Diseases in Primary Care

## The Family Healthware™ Impact Trial

Suzanne M. O'Neill, MA, MS, PhD, Wendy S. Rubinstein, MD, PhD, Catharine Wang, PhD, Paula W. Yoon, ScD, MPH, Louise S. Acheson, MD, MS, Nan Rothrock, PhD, Erin J. Starzyk, MPH, Jennifer L. Beaumont, MS, James M. Galliher, PhD, Mack T. Ruffin IV, MD, MPH, for the Family Healthware™ Impact Trial group

---

**Context:** Family history is a risk factor for many common chronic diseases, yet it remains underutilized in primary care practice.

**Background:** Family Healthware™ is a self-administered, web-based tool that assesses familial risk for CHD; stroke; diabetes; and colorectal, breast, and ovarian cancer, and provides a personalized prevention plan based on familial risk. The Family Healthware Impact Trial evaluated the tool.

**Design:** In this cluster RCT, participants completed baseline and 6-month follow-up surveys. The intervention group used Family Healthware directly after the baseline survey. Controls used the tool after completing the follow-up survey.

**Setting/ participants:** Patients aged 35–65 years with no known diagnosis of these six diseases were enrolled from 41 primary care practices.

**Main outcome measures:** The prevalence of family-history–based risk for coronary heart disease (CHD); stroke; diabetes; and colorectal, breast, and ovarian cancer was determined in a primary care population.

**Results:** From 2005 to 2007, 3786 participants enrolled. Data analysis was undertaken from September 2007 to March 2008. Participants had a mean age of 50.6 years and were primarily white (91%) women (70%). Of the 3585 participants who completed the risk assessment tool, 82% had a strong or moderate familial risk for at least one of the diseases: CHD (strong=33%, moderate=26%); stroke (strong=15%, moderate=34%); diabetes (strong=11%, moderate=26%); colorectal cancer (strong=3%, moderate=11%); breast cancer (strong=10%, moderate=12%); and ovarian cancer (strong=4%, moderate=6%). Women had a significantly ( $p<0.04$ ) higher familial risk than men for all diseases except colorectal and ovarian cancer. Overweight participants were significantly ( $p\leq 0.02$ ) more likely to have a strong family history for CHD, stroke, and diabetes. Older participants were significantly ( $p\leq 0.02$ ) more likely to report a strong family history for CHD and stroke as well as colorectal and breast cancer.

**Conclusions:** This self-administered, online tool delineated a substantial burden of family-history–based risk for these chronic diseases in an adult, primary care population.

**Trial registration:** NCT00164658.

(Am J Prev Med 2009;36(6):506–514) © 2009 American Journal of Preventive Medicine

---

From the Center for Medical Genetics (O'Neill, Rubinstein), the Center on Outcomes Research and Education (Rothrock, Beaumont), NorthShore University HealthSystem (formerly Evanston Northwestern Healthcare), Evanston; the Department of Medicine, Feinberg School of Medicine, Northwestern University; the Department of Epidemiology, University of Illinois at Chicago (Starzyk), Chicago, Illinois; Fox Chase Cancer Center (Wang), Philadelphia, Pennsylvania; Office of Public Health Genomics, CDC (Yoon), Atlanta, Georgia; the Departments of Family Medicine and Reproduc-

ive Biology and the Case Comprehensive Cancer Center, University Hospitals and Case Western Reserve University (Acheson), Cleveland, Ohio; the American Academy of Family Physicians' National Research Network (Galliher), Leawood, Kansas; and the Department of Family Medicine, University of Michigan (Ruffin), Ann Arbor, Michigan

Address correspondence and reprint requests to: Suzanne M. O'Neill, MA, MS, PhD, Center for Medical Genetics, 1000 Central Street, Suite 620, Evanston IL 60201. E-mail: [s-oneill@northwestern.edu](mailto:s-oneill@northwestern.edu).

## Introduction

Coronary heart disease (CHD), stroke, diabetes, and cancer account for approximately 60% of total deaths each year in the U.S.<sup>1,2</sup> Family history influences the risk of developing these multifactorial diseases. The relative risk for CHD; stroke; diabetes; and colorectal, breast, and ovarian cancer is approximately doubled if one first-degree relative is affected in middle age, and some family-history patterns carry a much stronger risk.<sup>3–10</sup> Knowledge of family-health history can guide risk-specific disease prevention, potentially reducing the burden of these chronic diseases.<sup>11,12</sup> Yet, owing to constraints on time, competing demands, and the complexity of familial-risk interpretation, systematic collection and assessment of detailed family-health histories rarely are done in primary care practice.<sup>13–18</sup> Thus, the effects are mostly unknown of systematically identifying and communicating the familial risk of disease to healthy adults. Likewise, data are very limited on the prevalence of family-health history that increases patients' risk for common chronic diseases.<sup>19–21</sup>

As part of a public health initiative to evaluate the use of family-health history for risk assessment and prevention, the CDC created Family Healthware™, an interactive online tool that provides personalized familial-risk assessments based on an individual's family history of six common chronic diseases as well as prevention plans with recommendations for lifestyle changes and screening tests. The tool systematically collects and records family-history information for CHD; stroke; diabetes; and colorectal, breast, and ovarian cancer by specifically asking about the occurrence of each disease (yes, no, don't know) as well as the age of disease onset (in 5-year increments) in every first- and second-degree relative. The software analyzes the user input, generating a three-tiered family-history–based risk assessment (see online appendix at [www.ajpm-online.net](http://www.ajpm-online.net)) for each disease based on algorithms assessing the number of affected relatives, age at onset, and related conditions (i.e., both breast and ovarian cancer in the same lineage).<sup>12,22</sup> In general, a weak familial risk is assigned to users with only one second-degree relative with late-onset disease or no family history of the disease. Moderate familial risk is consistent with either one first-degree or two second-degree relatives with late-onset disease. Strong familial risk is assigned when there is a first-degree relative with early-onset disease, multiple affected relatives, or a disease pattern suggesting a hereditary syndrome. The user's risk behaviors, including smoking, diet, physical activity, alcohol use, aspirin use, and current screening history are used to tailor risk-based preventive health messages. For example, a woman aged 35 years with a strong familial risk who had never had a mammogram would receive the message *You may benefit from breast cancer screening at a younger age than is usually*

*recommended. Talk to your health professional.* Details about the development and features of Family Healthware have been described elsewhere.<sup>22</sup>

In 2003 the CDC selected three academic centers to evaluate the clinical utility of this new tool: Evanston Northwestern Healthcare (ENH); the University of Michigan; and Case Western Reserve University (CWRU) with the American Academy of Family Physicians' (AAFP) National Research Network (NRN). The goal of the Family Healthware Impact Trial (FHITr) was to determine whether providing tailored family-health history messages influenced the adoption of healthy behaviors, recommended health screenings, and family and provider communication related to the six diseases. Additionally, the study aimed to measure the prevalence of three levels of family-history–based risk for the six diseases (weak, moderate, strong) among adults without a personal history of any of these diseases. This report presents the study methods and prevalence of family history for each of the six diseases in this primary care population.

## Methods

### Study Design

The FHITr used a practice-based, cluster-randomized design. Primary care practices were randomized to either the intervention or the control arm. In the intervention arm, participants first completed an online baseline survey, followed by Family Healthware, and subsequently received personalized risk assessment and prevention messages generated by the tool. The control group completed the baseline survey and received standard prevention messages about screening and healthy lifestyle choices recommended for the general population for the six diseases included in the tool. Approximately 6 months later, both the intervention and control groups completed a follow-up survey. The control group then also completed Family Healthware to enable comparisons not only between the intervention and control groups but also among familial-risk levels.

### Pretest and Posttest Surveys

A computer-administered baseline survey was developed that measured demographics, health status, use of medical services, screening behaviors, lifestyle choices, and health beliefs. Health status was measured by the 12-item Short Form Health Survey.<sup>23</sup> Items assessing health behaviors were based on previously validated items from population-based studies.<sup>24,25</sup> Health beliefs were based on a conceptual model that incorporated elements of prevailing health behavior theory.<sup>26–30</sup> The assessment of perceived risk, perceived severity, worry, perceived control, self-efficacy, and response efficacy for each disease was based on single items to reduce responder burden.<sup>26</sup> The intent to adopt healthy behaviors and reduce unhealthy behaviors in the future was measured using a modified stages-of-change model,<sup>28–30</sup> because discrete behavior-change outcomes, such as an increase in exercise or the adoption of mammography screening, might not be captured

in the 6-month follow-up time. In addition, family-history communication patterns (among family members and physicians) were assessed, using an instrument developed by the investigative team. Participants were asked if they had talked with specific family members or any medical care provider about their family-health history, and then asked to indicate whether they had discussed particular topics pertaining to the risk and fear of getting the six diseases, medical screening, lifestyle changes, and genetic testing. Participants were also asked about potential barriers to the discussion of family-health history. Local experts at each site piloted questions for face validity. The questionnaire data-collection process was piloted at each site by people meeting the study criteria. The follow-up survey was modeled after the baseline survey to assess changes over time. The University of Michigan and

CWRU-AAFP NRN sites also created a survey for healthcare providers to assess visit characteristics, preventive services, and referrals.


### Participants and Recruitment

Researchers from each site recruited primary care practices affiliated with their organizations (ENH, the University of Michigan, CWRU-AAFP NRN). Within sites, each practice was randomly assigned to either the intervention or control arm, using site-specific randomization schemes. While essential aspects of study recruitment and consent were similar, site-specific differences are shown in Table 1. The 41 participating practices, including 187 participating clinicians in 13 states (Figure 1), enrolled patients at differ-

**Table 1.** Protocol details by site

	ENH	CWRU	UM
<b>Practice locations</b>	Hospital-based medical group and affiliates of Evanston Northwestern Healthcare (Chicago suburbs)	Primary care research network (community practices in 11 states: CA, CT, FL, GA, MT, NC, NJ, NV, OH, OR, VA)	Primary care clinics affiliated with University of Michigan Health System (Ann Arbor MI area)
<b>Practice types</b>	Internal medicine (21); family medicine (17); obstetrics/gynecology (4)	Family medicine (14)	Internal medicine (1); family medicine (5)
<b>Practice randomization</b>	Intervention/control 2:1	Intervention/control 1:1	Intervention/control 1:1
<b>Patient identification</b>	Upcoming scheduled office visit; EMR or paper chart review for age criteria	Upcoming scheduled office visit; record review for age criteria; systematic procedure for random selection if more eligible patients than could be invited in a given week	Existing patient lists; no scheduled visit required; EMR review for age criteria; physician review of patient invitation list
<b>Patient recruitment: initial contact</b>	Mailed invitation letter from physician, informed-consent document, opt-out postcard	Mailed invitation letter from physician, including study ID and login password; web portal for online consent	Mailed invitation letter from physician; opt-in postcard
<b>Patient recruitment: reminders</b>	Three telephone calls at 2-week intervals	One phone call, time permitting	Second invitation letter after 2–4 weeks
<b>Patient recruitment: consent</b>	On receipt of signed consent document, patient was mailed further info, study ID, and login password	Online consent followed by signed consent at time of scheduled visit. After December 2006, only online consent required	On receipt of opt-in postcard, informed-consent document mailed. On receipt of signed consent, patient was mailed further info, study ID, and login password
<b>Survey and Family Healthware™ completion</b>	Online at study website or telephone interview	Online at study website or MD office computer	Online at study website or Telephone interview
<b>Delivery of printed prevention messages</b>	In person at scheduled appointment (copy to MD at patient request)	In person at scheduled appointment (copy to patient and MD)	Mailed or e-mailed to patient; patient asked to bring to MD at next visit
<b>Questionnaires for physicians</b>	Not applicable	After patient appointment, paper questionnaire to measure visit characteristics, preventive services, and referrals; intervention-group physicians answered additional questions evaluating the utility of the Family Healthware™ report	All study participants given surveys to give to any healthcare provider seen after baseline assessment was completed in order to measure visit characteristics, preventive services, and referrals

CWRU, Case Western Reserve University–American Academy of Family Physicians' National Research Network; EMR, electronic medical record; ENH, Evanston Northwestern Healthcare; UM, University of Michigan Health System (Ann Arbor MI area)



ent times throughout the recruitment period. Participants were healthy adults aged 35–65 years. Exclusion criteria included a personal history of CHD, diabetes, stroke, or any cancer other than nonmelanoma skin cancer; the inability to speak or read English; and known pregnancy. All sites systematically identified potential participants from the practices' patient records (Table 1). Patients received invitation letters signed by their primary care physicians. Individual protocols were approved in 2004 by IRB's at all three centers, and a combined protocol was approved by the CDC's IRB. Recruitment took place from November 2005 to March 2007.

### Data Collection

The survey instruments and the Family Healthware tool were accessed through a dedicated website; the study databases were housed in two SQL servers maintained by ENH. Site coordinators monitored progress, using management databases created by ENH and AAFP. Subjects could log on at any time using unique usernames and passwords that enabled them to complete the instruments over multiple sessions, if needed. Automated time stamps recorded only the start of input and the generation of the Family Healthware report; thus, completion time for the tool was calculated only for those who finished in <60 minutes. It was assumed that longer time intervals represented individuals who did not complete the input in one consecutive sitting, because pilot testing indicated a mean input time of 20 minutes even for the largest families.

For usability reasons, surveys were designed with automated skip patterns. Most entries were mandatory to minimize missing data. Almost all participants (91%) completed all instruments online through the website or a computer in their doctor's office, although participants could also respond by telephone with data entered online by study personnel. For the most part, the latter occurred because of the time constraint of completing the Family Healthware tool before a participant's provider appointment instead of a reluctance to go online. Online participants received Family Healthware risk levels and messages instantly on-screen, but all participants were either mailed or given printed reports. Participants received a \$10 incentive after completing each survey.

### Main Outcome Measures and Analysis

This report presents characteristics of the study participants and the distributions of the familial-risk classification for each disease. Comparisons of these distributions were made on

	Intervention				Control			
	ENH	UM	CWR	Total	ENH	UM	CWR	Total
Practices	14	3	6	23	7	3	8	18
Median # physicians	5	10	1	5	5	9	1	2.5
Range	1–9	7–19	1–3	1–19	2–6	7–18	1–4	1–18
Median # patients enrolled	108	317	13	108	107	183	20	72
Range # patients enrolled	9–127	133–374	5–118	5–374	55–143	114–208	2–66	2–208

**Figure 1.** Family Healthware™ impact trial enrollment and retention

Recruitment percentage: Number of individuals consented/number of individuals invited

Retention percentage: Number of individuals who completed all study instruments/number of individuals who completed baseline survey

**Table 2.** Demographics of study participants by study arm

	Intervention arm n=2364 n (%) <sup>a</sup>	Control arm n=1422 n (%) <sup>a</sup>
<b>Gender</b>		
Male	688 (29)	460 (32)
Female	1676 (71)	962 (68)
<b>Age (years)</b>		
M (SD)	50.3 (8.4)	51.1 (8.0)
<b>Are you Hispanic or Latino?</b>		
Yes	58 (2)	29 (2)
<b>Race</b>		
White or Caucasian	2134 (90)	1320 (93)
Black or African American	87 (4)	35 (3)
Asian	70 (3)	31 (2)
Native Hawaiian or other Pacific Islander	2 (0.1)	2 (0.1)
American Indian, Alaska native	2 (0.1)	1 (0.1)
Other	69 (2.9)	33 (2.3)
<b>Marital status</b>		
Single, never married	203 (9)	96 (7)
Married/living with partner	1857 (79)	1135 (80)
Formerly married	304 (12)	191 (13)
<b>Level of education</b>		
≤Grade 11	22 (1)	8 (0.6)
High school graduate	189 (8)	115 (8)
Some college or technical school	453 (19)	274 (19)
College graduate	1700 (72)	1025 (72)
<b>Annual household income (\$) <sup>b</sup></b>		
<25,000	91 (4)	41 (3)
25,001–50,000	320 (16)	151 (12)
50,001–75,000	402 (19)	228 (18)
>75,000	1262 (61)	834 (66)
<b>Do you currently have any kind of health insurance?</b>		
Yes	2276 (96)	1380 (97)
<b>Number of visits to doctor in last year</b>		
M (SD)	4.6 (5.7)	4.7 (5.7)
<b>BMI</b>		
M (SD)	27.4 (6.2)	27.2 (5.7)
<b>It is important for my own health to know if diseases like cancer, diabetes, stroke, or heart disease run in my family.</b>		
Disagree	124 (5.2)	75 (5.3)
Neither agree or disagree	56 (2.4)	31 (2.2)
Agree	2184 (92.4)	1316 (92.5)

Note: The comparisons are between the study arms for each variable and are adjusted for clustering effects. There were no significant differences found for any of the variables.

<sup>a</sup>Unless otherwise noted

<sup>b</sup>Twelve percent not reported

gender, age, smoking status, BMI, and type of medical care practice. Generalized estimating equation methods were used to adjust for the clustering by practice in all comparisons among groups. Data analysis was conducted from September 2007 to March 2008 using SAS version 9.1.

## Results

### Demographics of the Study Population

While 4248 subjects were enrolled, 3786 actually completed the baseline survey. Overall the study had 18%

recruitment, 89% retention from time of consent to completion of the baseline survey, and 88% retention from baseline to follow-up (Figure 1).

The study population was mostly white (91%) women (70%) who were married (76%), insured (97%), and of relatively high SES, with a mean age of 50.6 years, as summarized in Table 2. (Full demographic data are available as Appendix B online at [www.ajpm-online.net](http://www.ajpm-online.net).) The distribution of participants by practice type was family practice, 1834 (48%); internal medicine, 1485 (39%); and obstetrics/gynecology, 467 (12%). There were no significant demographic differences between control and intervention groups or between online and telephone users.

### Familial-Risk Levels in the Primary Care Population

Family Healthcare was completed by 3585 participants. The mean completion time for a convenience sample of 1170 consecutive participants was 19.6 minutes (range: 5.5–59.6; median: 17.0; mode: 9.63). The distribution of familial-risk levels for each disease is summarized in Table 3. For both genders, CHD had the highest percentage in the strong-risk category, followed by stroke; diabetes; and breast, ovarian, and colorectal cancer. Overall, 82% of participants had a strong or moderate risk for one or more of the six diseases.

Women's reported family histories placed them at significantly higher familial risk than men for all diseases except colorectal and ovarian cancer ( $p < 0.04$ ), although men reported *don't know* more often when prompted for the disease history of their relatives ( $p < 0.001$ ). For both genders, the prevalence of *don't know* responses across all relatives ranged from 25% (breast and ovarian cancer) to 28% (CHD). This response was significantly more likely in second-degree versus first-degree relatives and for male versus female relatives ( $p < 0.001$ ) for all diseases. Overweight participants ( $BMI \geq 25$ ) were significantly more likely than normal-weight participants to have a strong familial risk for CHD, stroke, and diabetes ( $p \leq 0.02$ ). Those aged  $\geq 50$  years were significantly more likely to be classified in the strong-risk category for CHD, stroke, and colorectal and breast cancer than younger participants ( $p \leq 0.02$ ). There was no significant difference in familial-risk classification due to smoking status or recruitment practice type.

## Discussion

This study's results demonstrate that there is a substantial burden of family-history-based risk among unaffected adults aged 35–65 years who are seen in primary care practices. Although estimates of the prevalence of

**Table 3.** Stratification of familial risk for common diseases as calculated by the Family Healthware™ risk assessment tool ( $n=3585$ )

	Familial risk						<i>p</i> -value <sup>a</sup>
	Weak		Moderate		Strong		
	Men <i>n</i> (%)	Women <i>n</i> (%)	Men <i>n</i> (%)	Women <i>n</i> (%)	Men <i>n</i> (%)	Women <i>n</i> (%)	
Coronary heart disease	494 (46)	955 (38)	265 (24)	673 (27)	321 (30)	877 (35)	0.010
Stroke	620 (57)	1232 (49)	311 (29)	891 (36)	149 (14)	382 (15)	0.007
Diabetes	695 (64)	1543 (62)	294 (27)	651 (26)	91 (8)	311 (12)	0.040
Colorectal cancer	938 (87)	2146 (86)	116 (11)	294 (12)	26 (2)	65 (3)	0.382
Breast cancer	883 (82)	1906 (76)	109 (10)	335 (13)	88 (8)	264 (11)	0.001
Ovarian cancer	984 (91)	2258 (90)	48 (4)	150 (6)	48 (4)	97 (4)	0.380

<sup>a</sup>The comparisons of percentages in each risk level are between men and women and are adjusted for clustering effects (*p*-values refer to the distribution across risk levels).

family history of common diseases have been made from national surveys,<sup>31–33</sup> these data represent the first based on more-detailed family histories that have been collected in primary care settings. These data will be invaluable in planning, implementing, and analyzing future studies on family-health history in primary care.

### Accuracy of Estimates and Variability Among Subgroups

Because Family Healthware risk algorithms depend on reported disease in both first- and second-degree relatives, this study's prevalence figures may underestimate actual familial risk. The accuracy of self-report of familial disease has been examined in a number of studies<sup>34–37</sup> using various standards of reference such as medical records, death certificates, and confirmation by relatives. In general, specificity is high and sensitivity is somewhat lower, indicating that individuals are better at reporting the absence of disease in relatives than the presence of a specific type of disease. Sensitivity has been shown to be lower in second-degree relatives compared to first-degree relatives, a finding in agreement with the preponderance of *don't know* responses for second-degree relatives in this study. In addition, most studies examining the accuracy of self-reported family history have been done in populations affected by the disease of interest, whereas this study's participants were unaffected by any of the six assessed diseases. While this might result in some underreporting of affected relatives due to decreased salience, several case-control studies have shown little difference in accuracy between affected and unaffected informants.<sup>36,38,39</sup>

Women had higher calculated family risks than men for all diseases except colorectal and ovarian cancer. However, the percentage of subjects stratified by Family Healthware into strong- or moderate-risk categories was lower for these two cancers than for the other diseases, and therefore the power to detect gender differences may have been limited. This finding may be due to recall or informational bias, with women reporting, actually knowing more, or both, about the disease

histories of family members. Other studies have compared men's and women's accuracy in reporting a family history of cancer. Some studies<sup>39–41</sup> showed no difference, while others<sup>38,42–44</sup> showed that women reported their family history more accurately than men. Theoretically, for unaffected individuals, family history should not vary by gender. If men do underreport family history when using a screening tool such as Family Healthware, the actual prevalence of the familial risk may be higher than reported here. Verification of family histories was beyond the scope of this study.

Although the risk algorithms did not include any personal risk factors such as age, it was found that adults aged  $\geq 50$  years had higher familial risks than their younger counterparts for most diseases. Studies of age as a determinant of family-history accuracy have had varying results.<sup>37,45</sup> For adult-onset diseases, older individuals may be more likely to have affected first- and second-degree relatives than younger people and may be better sources for familial-risk assessment when using tools that do not include more-distant relatives. However, prevention interventions may be more effective in younger individuals, pointing to a need to encourage families to communicate about familial risk.

A novel although not unexpected finding is the difference in risk classification for overweight participants. The relationship of being overweight to a family history of diabetes and cardiovascular disease reflects the consequences of genetic susceptibilities, shared environment, and common behaviors,<sup>46</sup> consistent with the familial aggregation of metabolic syndrome. In contrast, smoking status is not associated with familial-risk classification for the diseases assessed in this study population.

The validity of the risk-stratification algorithms is essential to the overall utility of the Family Healthware tool. Although population-based data to validate familial-risk algorithms are few, several recent studies<sup>32,33,47</sup> have assessed the performance of risk-stratification rules similar to those used in Family Healthware. Table 4 shows that they have fairly good agreement with this study's

**Table 4.** Prevalence of familial risk in selected studies

Study	Disease	Ascertainment	n	Familial risk		
				Weak (%)	Moderate (%)	Strong (%)
Scheuner (2006) <sup>32</sup>	CHD	HealthStyles 2003	4,035	56.8	11.7	31.5
FHITr	CHD	Primary care	3,585	40.6	26.41	32.9
Hariri (2006) <sup>47</sup>	Diabetes	HealthStyles 2004	4,345	65	19	16
Valdez (2007) <sup>33</sup>	Diabetes	NHANES 1999–2004	16,388	70	23	7
FHITr	Diabetes	Primary care	3,585	61	28	11

CHD, coronary heart disease; FHITr, Family Healthware™ impact trial; NHANES, National Health and Nutrition Examination Survey

prevalence estimates. The FHITr prevalence of strong familial CHD risk is similar to the Scheuner study,<sup>32</sup> although the current study's population has a higher percentage in the moderate-risk group. The FHITr prevalence of strong familial diabetes risk lies between the two existing studies,<sup>33,47</sup> but again, the prevalence of moderate risk is higher. While it is possible that an active primary care population might have a higher family-history burden than the general population, further validation studies will be needed to replicate these findings.

### Limitations

This study provides a unique insight into the distribution of family-history–based risk for six common diseases in primary care practices. The observation that almost all FHITr participants understand that family history is a risk factor for disease and believe that knowing their family history is important for their own health is not necessarily evidence that this sample had self-selected for interest in family history. In a national study<sup>48</sup> about awareness of family history, 96% of survey respondents reported that knowing their family history was important for their own health. The limited diversity of this study's population, racially and ethnically, limits the generalizability of results from the FHITr. Study participants were highly educated patients with health insurance who were, for the most part, able to use computers to access the study materials online. Data are not available to compare the race, ethnicity, educational attainment, or health-insurance status of patients invited versus those who participated. Replication in more-diverse populations is needed.

Although personal risk factors such as smoking, diet, physical activity, and BMI are incorporated in the tailored messaging, the Family Healthware risk algorithms do not include these factors. In addition, other established risk factors are not included, such as the biopsy history incorporated in the Gail model<sup>49</sup> for breast cancer, cholesterol levels for CHD, and even family-history details associated with hereditary colorectal cancer (polyps, hereditary nonpolyposis colorectal cancer–associated endometrial cancer). These limitations can be addressed in future versions of the tool.

Finally, Family Healthware provides familial-risk assessment for men related to breast and ovarian cancer.

Obviously, this is not always relevant to a male individual's personal risk, but it is important to female family members. It is not clear how receptive men or their healthcare providers may be to messages about preventing these two cancers.

### Familial-Risk Stratification for Screening and Prevention

Prevention measures exist for all of the diseases assessed, and familial-risk stratification can identify those people most likely to benefit from targeted preventive strategies. One impetus for assessing risk for multiple diseases in Family Healthware was the recognition that the same risk-reducing behaviors contribute to preventing a variety of chronic diseases. However, the adoption of Family Healthware or other similar tools will be limited until clinical benefits can be shown. A few population-based studies have found that having a family history of a chronic disease was associated with a greater awareness of risk and reported risk-reducing behaviors,<sup>50–52</sup> but data from clinical practice are very limited.

Computerized family-history tools that include sophisticated risk assessment algorithms are fast being developed.<sup>22,53–59</sup> The FHITr trial has demonstrated that a segment of the primary care population is both interested in family-health history (the study retention was high) and able to easily use a computerized risk assessment tool outside of the clinical setting (completion time was quite modest). More validation studies in diverse populations are critically needed before the widespread dissemination of these tools.

The Family Healthware™ Impact Trial (FHITr) was supported through cooperative agreements between the CDC and the Association for Prevention Teaching and Research (ENH#U50/CCU300860 TS-1216) and the American Association of Medical Colleges (UM#U36/CCU319276 MM-0789 and CWR# U36/CCU319276 MM0630).

Suzanne O'Neill and Mack Ruffin, principal investigators, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The data, in part, were presented as abstracts at The American Society of Human Genetics annual meeting in 2007, the National Prevention and Health Promotion Summit in 2007, and the Sixth American Association for Cancer

Research International Conference on Frontiers in Cancer Prevention Research in 2007.

No financial disclosures were reported by the authors of this paper.

The FHITr group consists of the collaborators listed below.

From the CDC: Paula W. Yoon, ScD, MPH; Rodolfo Valdez, PhD; Margie Irizarry-De La Cruz, MPH; Muin J. Khoury MD, PhD; Cynthia Jorgensen, DrPH

From the Rand Corporation: Maren T. Scheuner, MD, MPH  
From Evanston Northwestern Healthcare: Suzanne M. O'Neill, MA, MS, PhD, Principal Investigator; Wendy S. Rubinstein, MD, PhD, Principal Investigator; Nan Rothrock, PhD; Jennifer L. Beaumont, MS; Shaheen Khan, MS, MBA, MPH; Dawood Ali, MS

From the University of Illinois at Chicago: Erin J. Starzyk, MPH

From Fox Chase Cancer Center: Catharine Wang, PhD

From the University of Michigan: Mack T. Ruffin IV, MD, MPH, Principal Investigator; Donald Nease, MD, Principal Investigator

From Case Western Reserve University: Louise S. Acheson, MD, MS, Principal Investigator; Stephen J. Zyzanski, PhD; Georgia L. Wiesner, MD; James Werner, PhD

From the University of Rochester: Robert Gramling, MD, PhD

From the American Academy of Family Practice National Research Network: Wilson D. Pace, MD, Principal Investigator; James M. Galliher, PhD; Elias Brandt, BS, BA

## References

- Hamilton BE, Minino AM, Martin JA, Kochanek KD, Strobino DM, Guyer B. Annual summary of vital statistics: 2005. *Pediatrics* 2007;119:345–60.
- Minino AM, Heron MP, Murphy SL, Kochanek KD. Deaths: final data for 2004. *Natl Vital Stat Rep* 2007;55:1–119.
- Colditz GA, Willett WC, Hunter DJ, et al. Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. *JAMA* 1993;270:338–43.
- Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. *N Engl J Med* 1994;331:1669–74.
- Harrison TA, Hindorff LA, Kim H, et al. Family history of diabetes as a potential public health tool. *Am J Prev Med* 2003;24:152–9.
- Hunt SC, Gwinn M, Adams TD. Family history assessment: strategies for prevention of cardiovascular disease. *Am J Prev Med* 2003;24:136–42.
- Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, et al. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. *PLoS Med* 2004;1:e65.
- Jood K, Ladenvall C, Rosengren A, Blomstrand C, Jern C. Family history in ischemic stroke before 70 years of age: the Sahlgrenska Academy Study on Ischemic Stroke. *Stroke* 2005;36:1383–7.
- Colditz GA, Stampfer MJ, Willett WC, Rosner B, Speizer FE, Hennekens CH. A prospective study of parental history of myocardial infarction and coronary heart disease in women. *Am J Epidemiol* 1986;123:48–58.
- Scheuner MT, Whitworth WC, McGruder H, Yoon PW, Khoury MJ. Expanding the definition of a positive family history for early-onset coronary heart disease. *Genet Med* 2006;8:491–501.
- Yoon PW, Scheuner MT, Khoury MJ. Research priorities for evaluating family history in the prevention of common chronic diseases. *Am J Prev Med* 2003;24:128–35.
- Scheuner MT, Wang SJ, Raffel LJ, Larabell SK, Rotter JI. Family history: a comprehensive genetic risk assessment method for the chronic conditions of adulthood. *Am J Med Genet* 1997;71:315–24.
- Acheson LS, Wiesner GL, Zyzanski SJ, Goodwin MA, Stange KC. Family history-taking in community family practice: implications for genetic screening. *Genet Med* 2000;2:180–5.
- Rich EC, Burke W, Heaton CJ, et al. Reconsidering the family history in primary care. *J Gen Intern Med* 2004;19:273–80.
- Acheson L. Fostering applications of genetics in primary care: what will it take? *Genet Med* 2003;5:63–5.
- Emery J, Rose P. Expanding the role of the family history in primary care. *Br J Gen Pract* 1999;49:260–1.
- Emery J. Evaluation of questionnaire on cancer family history in general practice. Principal role of primary care is not to seek out those at increased genetic risk. *BMJ* 2000;320:186–7.
- Suther S, Goodson P. Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature. *Genet Med* 2003;5:70–6.
- Annis AM, Caulder MS, Cook ML, Duquette D. Family history, diabetes, and other demographic and risk factors among participants of the National Health and Nutrition Examination Survey 1999–2002. *Prev Chronic Dis* 2005;2:A19.
- Johnson N, Lancaster T, Fuller A, Hodgson SV. The prevalence of a family history of cancer in general practice. *Fam Pract* 1995;12:287–9.
- Frezzo TM, Rubinstein WS, Dunham D, Ormond KE. The genetic family history as a risk assessment tool in internal medicine. *Genet Med* 2003;5:84–91.
- Yoon PW, Scheuner MT, Jorgensen C, Khoury MJ. Family Healthware™: developing family healthware, a family history screening tool to prevent common chronic diseases. *Prev Chronic Dis* 2009;6:A33.
- Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. *Med Care* 1996;34:220–33.
- CDC. Behavioral Risk Factor Surveillance System Survey Questionnaire. Atlanta GA: USDHHS, CDC.
- CDC. National Health Information Survey. Atlanta GA: USDHHS, CDC.
- Wang C, O'Neill SM, Rothrock N, et al. Comparison of risk perceptions and beliefs across common chronic diseases. *Prev Med* 2008;48:197–202.
- Witte K, Cameron KA, McKeon JK, Berkowitz JM. Predicting risk behaviors: development and validation of a diagnostic scale. *J Health Commun* 1996;1:317–41.
- Prochaska JO, Velicer WF, Rossi JS, et al. Stages of change and decisional balance for 12 problem behaviors. *Health Psychol* 1994;13:39–46.
- Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. *Am J Health Promot* 1997;12:38–48.
- Weinstein ND. Perceived probability, perceived severity, and health-protective behavior. *Health Psychol* 2000;19:65–74.
- Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ. Population-based study of the prevalence of family history of cancer: implications for cancer screening and prevention. *Genet Med* 2006;8:571–5.
- Scheuner MT, Whitworth WC, McGruder H, Yoon PW, Khoury MJ. Familial risk assessment for early-onset coronary heart disease. *Genet Med* 2006;8:525–31.
- Valdez R, Yoon PW, Liu T, Khoury MJ. Family history and prevalence of diabetes in the U.S. population: the 6-year results from the National Health and Nutrition Examination Survey (1999–2004). *Diabetes Care* 2007;30:2517–22.
- Bensen JT, Liese AD, Rushing JT, et al. Accuracy of proband reported family history: the NHLBI Family Heart Study (FHS). *Genet Epidemiol* 1999;17:141–50.
- Kahn LB, Marshall JA, Baxter J, Shetterly SM, Hamman RF. Accuracy of reported family history of diabetes mellitus. Results from San Luis Valley Diabetes Study. *Diabetes Care* 1990;13:796–8.
- Kee F, Tiret L, Robo JY, et al. Reliability of reported family history of myocardial infarction. *BMJ* 1993;307:1528–30.
- Qureshi N, Wilson B, Santaguida P, et al. Collection and use of cancer family history in primary care. Evidence Report/Technology Assessment No. 159. AHRQ Publication No. 08-E001. Rockville MD: Agency for Healthcare Research and Quality, 2007.
- Kerber RA, Slattery ML. Comparison of self-reported and database-linked family history of cancer data in a case-control study. *Am J Epidemiol* 1997;146:244–8.
- Mitchell RJ, Brewster D, Campbell H, et al. Accuracy of reporting of family history of colorectal cancer. *Gut* 2004;53:291–5.
- Aitken J, Bain C, Ward M, Siskind V, MacLennan R. How accurate is self-reported family history of colorectal cancer? *Am J Epidemiol* 1995;141:863–71.
- Sijmons RH, Boonstra AE, Reefhuis J, et al. Accuracy of family history of cancer: clinical genetic implications. *Eur J Hum Genet* 2000;8:181–6.
- Kupfer SS, McCaffrey S, Kim KE. Racial and gender disparities in hereditary colorectal cancer risk assessment: the role of family history. *J Cancer Educ* 2006;21:S32–S36.

43. Ziogas A, Anton-Culver H. Validation of family history data in cancer family registries. *Am J Prev Med* 2003;24:190–8.
44. Glanz K, Grove J, Le ML, Gotay C. Underreporting of family history of colon cancer: correlates and implications. *Cancer Epidemiol Biomarkers Prev* 1999;8:635–9.
45. Murff HJ, Peterson NB, Greevy R, Zheng W. Impact of patient age on family cancer history. *Genet Med* 2006;8:438–42.
46. Tang W, Hong Y, Province MA, et al. Familial clustering for features of the metabolic syndrome: the National Heart, Lung, and Blood Institute (NHLBI) Family Heart Study. *Diabetes Care* 2006;29:631–6.
47. Hariri S, Yoon PW, Qureshi N, Valdez R, Scheuner MT, Khoury MJ. Family history of type 2 diabetes: a population-based screening tool for prevention? *Genet Med* 2006;8:102–8.
48. CDC. Awareness of family health history as a risk factor for disease—U.S., 2004. *MMWR Morb Mortal Wkly Rep* 2004;53:1044–7.
49. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. *J Natl Cancer Inst* 1989;81:1879–86.
50. Audrain-McGovern J, Hughes C, Patterson F. Effecting behavior change: awareness of family history. *Am J Prev Med* 2003;24:183–9.
51. Baptiste-Roberts K, Gary TL, Beckles GL, et al. Family history of diabetes, awareness of risk factors, and health behaviors among African Americans. *Am J Public Health* 2007;97:907–12.
52. Qureshi N, Kai J. Informing patients of familial diabetes mellitus risk: how do they respond? A cross-sectional survey. *BMC Health Serv Res* 2008;8:37.
53. Sweet KM, Bradley TL, Westman JA. Identification and referral of families at high risk for cancer susceptibility. *J Clin Oncol* 2002;20:528–37.
54. Skinner CS, Rawl SM, Moser BK, et al. Impact of the Cancer Risk Intake System on patient–clinician discussions of tamoxifen, genetic counseling, and colonoscopy. *J Gen Intern Med* 2005;20:360–5.
55. Jones JL, Hughes KS, Kopans DB, et al. Evaluation of hereditary risk in a mammography population. *Clin Breast Cancer* 2005;6:38–44.
56. Hampton T. Family health history. *JAMA* 2005;294:3075.
57. Emery J. The GRAIDS Trial: the development and evaluation of computer decision support for cancer genetic risk assessment in primary care. *Ann Hum Biol* 2005;32:218–27.
58. O’Neill SM. Communicating familial risk—my generations. Proceedings of the CDC workshop Family History Tools to Improve the Public’s Health; 2005 Nov 17–18; Atlanta GA.
59. Acheson LS, Zyzanski SJ, Stange KC, Deptowicz A, Wiesner GL. Validation of a self-administered, computerized tool for collecting and displaying the family history of cancer. *J Clin Oncol* 2006;24:5395–402.

## Appendix

### Supplementary Data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.amepre.2009.03.002.

#### Did you know?

You can link from cited references to abstracts and full-text articles in other participating journals.

Visit [www.ajpm-online.net](http://www.ajpm-online.net) today to see what else is new online!